Evidence map›Paper›PMID 26550687›Full record

Trial reportAmerican journal of respiratory and critical care medicine2016

Lung Deflation and Cardiovascular Structure and Function in Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial.

Ian S Stone, Neil C Barnes, Wai-Yee James, Dawn Midwinter, Redha Boubertakh, Richard Follows, Leonette John, Steffen E Petersen

Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph

Trial report in American journal of respiratory and critical care medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03611699 (Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients), which is not on this map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
12.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03611699 phase4completednot on this mapstarted 2019, after this paper: background citation

Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients

TypeinterventionalSponsorGary L. PierceRan2019 to 2020Enrolled15ConditionsCOPDArmsUmeclidinium / Vilanterol Dry Powder Inhaler, Placebo
3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 121 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Allopurinol in Patients with Pulmonary Hypertension Associated with Chronic Lung Disease.International journal of chronic obstructive pulmonary disease · 2020
    Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Observational
  12. Review
  13. Impact of Frailty on Major Adverse Cardiovascular Events in Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2025
    Article
  14. Article
  15. Pulmonary rehabilitation and physical interventions.European respiratory review : an official journal of the European Respiratory Society · 2023
    Review
  16. The Diagnosis and Treatment of COPD and Its Comorbidities.Deutsches Arzteblatt international · 2023
    Review
  17. Article
  18. Article
  19. Article
  20. Regular Inhaled Corticosteroids Use May Protect Against Severe COVID-19 Outcome in COPD.International journal of chronic obstructive pulmonary disease · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Ian S Stone1 Department of Respiratory Medicine, The London Chest Hospital, Barts Health NHS Trust, London, United Kingdom.
Neil C Barnes2 William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; and.
Wai-Yee James1 Department of Respiratory Medicine, The London Chest Hospital, Barts Health NHS Trust, London, United Kingdom.
Dawn Midwinter3 Global Respiratory Department, GlaxoSmithKline, Stockley Park, Uxbridge, United Kingdom.
Redha Boubertakh2 William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; and.
Richard Follows3 Global Respiratory Department, GlaxoSmithKline, Stockley Park, Uxbridge, United Kingdom.
Leonette John1 Department of Respiratory Medicine, The London Chest Hospital, Barts Health NHS Trust, London, United Kingdom.
Steffen E Petersen2 William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; and.
Queen Mary University of London · GBBarts Health NHS Trust · GBGlaxoSmithKline (United Kingdom) · GB

Funding

Medical Research Council MR/K006584/1
6 · The paper itself

Abstract

rationalePatients with chronic obstructive pulmonary disease develop increased cardiovascular morbidity with structural alterations.

objectivesTo investigate through a double-blind, placebo-controlled, crossover study the effect of lung deflation on cardiovascular structure and function using cardiac magnetic resonance.

methodsForty-five hyperinflated patients with chronic obstructive pulmonary disease were randomized (1:1) to 7 (maximum 14) days inhaled corticosteroid/long-acting β2-agonist fluticasone furoate/vilanterol 100/25 μg or placebo (7-day minimum washout). Primary outcome was change from baseline in right ventricular end-diastolic volume index versus placebo. MEASUREMENTS AND MAIN

resultsThere was a 5.8 ml/m(2) (95% confidence interval, 2.74-8.91; P < 0.001) increase in change from baseline right ventricular end-diastolic volume index and a 429 ml (P < 0.001) reduction in residual volume with fluticasone furoate/vilanterol versus placebo. Left ventricular end-diastolic and left atrial end-systolic volumes increased by 3.63 ml/m(2) (P = 0.002) and 2.33 ml/m(2) (P = 0.002). In post hoc analysis, right ventricular stroke volume increased by 4.87 ml/m(2) (P = 0.003); right ventricular ejection fraction was unchanged. Left ventricular adaptation was similar; left atrial ejection fraction improved by +3.17% (P < 0.001). Intrinsic myocardial function was unchanged. Pulmonary artery pulsatility increased in two of three locations (main +2.9%, P = 0.001; left +2.67%, P = 0.030). Fluticasone furoate/vilanterol safety profile was similar to placebo.

conclusionsPharmacologic treatment of chronic obstructive pulmonary disease has consistent beneficial and plausible effects on cardiac function and pulmonary vasculature that may contribute to favorable effects of inhaled therapies. Future studies should investigate the effect of prolonged lung deflation on intrinsic myocardial function. Clinical trial registered with www.clinicaltrials.gov (NCT 01691885).

Indexed as

Administration, InhalationAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsAgedAndrostadienesBenzyl AlcoholsBronchodilator AgentsChlorobenzenesCross-Over StudiesDrug CombinationsFemaleForced Expiratory VolumeHeartHumansLungMagnetic Resonance ImagingAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsAndrostadienesBenzyl AlcoholsBronchodilator AgentsChlorobenzenesDrug Combinationsfluticasone furoatevilanterolcardiac functioncardiac magnetic resonancechronic obstructive pulmonary diseasefluticasone furoate/vilanterollung hyperinflation

Identifiers

PMID26550687
PMCPMC5440091
OpenAlexW2327645667

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.